LORDS

How can the UK remain attractive to the pharmaceutical industry?

28 November 2017

The House of Lords Science and Technology Committee continues taking evidence for its inquiry into Life Sciences and the Industrial Strategy. The Committee questions academics and representatives of the American Pharmaceutical Group.

Purpose of sessions

The Committee hears the views of the US pharmaceutical industry on why some pharmaceutical companies have moved out of the UK in recent years and question leading academics on why it is difficult for the UK to match the success of the US in the life sciences sector.

Witnesses

Tuesday 28 November in Committee Room 4A, Place of Westminster

At 10.10am

  • Dr Michael Hopkins, Senior Lecturer, Science Policy Research Unit, University of Sussex
  • Professor Andy Westwood, Member of the Industrial Strategy Commission, and Professor of Government Practice and Vice Dean of Humanities at the University of Manchester

At 11.00am

  • Erik Nordkamp, Chair of the American Pharmaceutical Group and UK Managing Director, Pfizer
  • Mark Hicken, Vice Chair of the American Pharmaceutical Group and UK Managing Director, Janssen
  • Louise Houson, UK Managing Director, MSD

Possible questions

Questions likely to be covered in the sessions include:

  • How likely is it that the UK can meet the goal of four companies in life sciences with market capitalisation of £20bn in the next 10 years?
  • What impact is the relocation of the European Medicines Agency from London likely to have?
  • How would you describe the current relationship between the NHS and industry?

Further information

Image: iStockphoto

More news on: Parliament, government and politics, Parliament, Science and technology, Research and innovation, House of Lords news, Lords news, Committee news

Share this page